Trial · NCT01335581
Study of Laser Treatment of Melasma
NCT01335581, Not applicable, Completed, ConBio, a Cynosure Company; results first posted 2020-12-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Laser Treatment of Melasma. Trials, record NCT01335581. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01335581
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Laser Treatment of Melasma
- NCT number
- NCT01335581
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 18 participants, actual
- Lead sponsor
- ConBio, a Cynosure Company
- Conditions
- Refractory Mixed Type Melasma
- Interventions
- Q-Switched Nd:YAG Laser (RevLite), Retin-A and microdermabrasion
- First posted
- 2011-04-14
- Last updated
- 2022-01-13
- Results first posted
- 2020-12-28
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Melasma Area Severity Assessment (MASI) Score Change From Baseline to Follow Up | 3 Months | The severity of the melasma is assessed based on a photographic scale. The scale ranges from 0 to 48, with 48 being the most severe. A decrease in the MASI score from the baseline to the follow up corresponds with decreasing severity. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Melasma Area Severity Assessment (MASI) Score Change From Baseline to Follow Up | 3 Months | 8 subjects did not attend the 3 month follow up, and 2 subjects attended but did not complete their MASI score. | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Melasma Area Severity Assessment (MASI) Score Change From Baseline to Follow Up | Laser Treatment | -5.6 | Standard Deviation 6.9 | score on a scale | |
| Melasma Area Severity Assessment (MASI) Score Change From Baseline to Follow Up | Control Group | 4.7 | Standard Deviation 9.2 | score on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Laser Treatment | 9 | |
| Overall Study | STARTED | Control Group | 9 | |
| Overall Study | COMPLETED | Laser Treatment | 5 | |
| Overall Study | COMPLETED | Control Group | 3 | |
| Overall Study | NOT COMPLETED | Laser Treatment | 4 | |
| Overall Study | NOT COMPLETED | Control Group | 6 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dryness | Skin and subcutaneous tissue disorders | Laser Treatment | 0 | 9 | |
| other | Dryness | Skin and subcutaneous tissue disorders | Control Group | 1 | 9 | |
| other | Hyperpigmentation | Skin and subcutaneous tissue disorders | Laser Treatment | 0 | 9 | |
| other | Hyperpigmentation | Skin and subcutaneous tissue disorders | Control Group | 1 | 9 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Laser Treatment | 0 | 9 |
| Total, all-cause mortality | Control Group | 0 | 9 |
| Total, other adverse events | Laser Treatment | 0 | 9 |
| Total, other adverse events | Control Group | 1 | 9 |
| Total, serious adverse events | Laser Treatment | 0 | 9 |
| Total, serious adverse events | Control Group | 0 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Laser Treatment vs Control Group: deaths from any cause | Trial comparisons |
| Laser Treatment vs Control Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01335581
GET https://conductscience.org/api/trials/v1/NCT01335581/registered